Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook
December 15, 2025 — Merck & Co., Inc. (NYSE: MRK) traded around $99.59 in Monday afternoon action, down about 0.23% on the day, as investors balanced a fresh wave of bullish analyst updates against a busy set of catalysts spanning Winrevair, Keytruda, vaccines, and headline regulatory scrutiny. The setup for MRK stock into year-end is increasingly about “what comes after Keytruda,” and the story is getting more layered: an expanded European pathway for Winrevair (sotatercept), a higher dividend heading into the ex-dividend date, and new legal and policy crosswinds around Merck’s newer product rollouts and the U.S. vaccine environment. What’s